Chemo-immunotherapy beats BRAF/MEK inhibitors in response rates for BRAF-mutant lung cancer

Education and decision-support only — not a medical device or personalised advice. Always discuss your specific situation with your specialist team.

Scope note: This article covers BRAF-targeted therapy in lung cancer as background for understanding cross-tumour BRAF biology. Treatment decisions for melanoma differ — see our Melanoma treatment overview for melanoma-specific guidance.

Context

A 2025 multicentre retrospective cohort compared first‑line immunotherapy ± chemotherapy with BRAF + MEK inhibitors in patients who have BRAF V600E‑mutated metastatic non‑small‑cell lung cancer. The study found a higher tumor‑shrinkage rate with chemo‑immunotherapy ¹. Because the analysis was retrospective and not randomized, the results are hypothesis‑generating rather than definitive.

Chemo‑Immunotherapy Improves Response Rates

In the FRONT‑BRAF cohort, a larger proportion of patients receiving immunotherapy ± chemotherapy achieved tumor reduction than those treated with BRAF + MEK inhibitors ¹. The authors suggested that chemotherapy may release tumor antigens, boosting immune recognition, whereas targeted therapy mainly blocks MAPK signaling without stimulating immunity. The benefit appeared across age and performance‑status groups, indicating broad relevance. However, selection bias cannot be ruled out; patients given chemo‑immunotherapy might have had more favorable baseline characteristics.

Safety Profile

Adverse‑event patterns differed between the two approaches. Chemo‑immunotherapy was linked to fatigue, nausea, and immune‑related inflammation such as colitis or pneumonitis, while BRAF + MEK inhibitors more often caused fever, skin rash, and liver‑enzyme elevations ¹. Most toxicities were manageable with dose adjustments or supportive care, but immune‑related events sometimes required steroids, which can increase infection risk. Because the study did not systematically grade severity, the true rate of high‑grade events remains uncertain.

Open Questions and Future Directions

Prospective randomized trials are needed to confirm whether the response advantage persists when patient selection is controlled. Biomarkers that predict benefit from chemo‑immunotherapy versus targeted therapy have not been identified; circulating tumor DNA dynamics are a potential clue, but no graded study has evaluated this in BRAF‑mutant NSCLC. The optimal sequencing—starting with chemo‑immunotherapy or reserving BRAF + MEK inhibitors for later lines—remains untested. Discuss these uncertainties with your oncologist and consider enrollment in clinical trials.

What This Means for You

Current evidence suggests chemo‑immunotherapy may produce higher tumor‑shrinkage rates than BRAF + MEK inhibitors for BRAF‑mutated lung cancer, but the data come from a retrospective study with inherent limitations. Talk with your oncology team about the strengths and gaps of the evidence, your overall health, and your preferences for treatment intensity and side‑effect monitoring. Ask about clinical‑trial options and plan regular imaging and symptom tracking to gauge response and toxicity.

If you develop new skin lesions or rashes, see a dermatologist promptly.

TL;DR

• Chemo‑immunotherapy showed higher response rates than BRAF + MEK inhibitors in a retrospective study.
• The study’s design limits causal inference.
• Discuss treatment options with your oncology team.
• Chemo‑immunotherapy has a distinct safety profile, including immune‑related toxicities.
• More research is needed to confirm these findings and define optimal sequencing.